Center Faculty

Please click on a name below to view that person's profile.

 
Lynn Bry, M.D., Ph.D.

Assistant Professor of Pathology, HMS
BWH Clinical Labs
(617) 732-7763
lbry@partners.org

Lynn Bry, M.D., Ph.D. is the Principal Investigator and Director of the Partners Biorepository for Medical Discovery (PBMD) at the Brigham and Women’s Hospital (BWH) where she is also the Director of the Specimen Bank. The PBMD is consenting patients at two Partners Healthcare institutions, BWH and MGH, to enable studies furthering biomarker development and validation for personalized medicine. Dr. Bry is an Assistant Professor of Pathology at Harvard Medical School and an Associate Medical Director in the Department of Pathology at BWH. She directs the Crimson Project (http://www.crimsonproject.org/) that has developed IT tools and infrastructure to support high-throughput and sample collection that occurs in a cost-effective and IRB-compliant manner. Working with i2b2 (Informatics for Integrating Biology with the Bedside, https://www.i2b2.org), an NIH-funded National Center for Biomedical Computing, Crimson has enabled many large-scale genomic studies by supplying tens of thousands of phenotyped samples at a fraction of the costs commonly incurred to obtain adequate materials.

Dr. Bry is a Board-certified pathologist and specializes in clinical laboratory testing in molecular diagnostics, microbiology and immunology. She routinely works with research groups to develop novel markers into diagnostic assays that can be run on platforms used in clinical laboratories. She also maintains an NIH-funded research laboratory, studying host-pathogen-commensal interactions in the gut.
 

 

 
Immaculata de Vivo, M.P.H., Ph.D.

Associate Professor of Medicine, HMS
(617) 432-1642
nhidv@channing.harvard.edu

Immaculata de Vivo, M.P.H., Ph.D. is Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) High-Throughput Taqman Genotyping Facility that is operated under Partners HealthCare Center for Personalized Genetic Medicine (PCPGM). Her research focuses on the discovery and characterization of genetic biological markers to assess disease susceptibility in human populations. Biological markers of interest include single nucleotide polymorphisms (SNPs), telomere length, and gene copy number variations (CNVs). The goal of Dr. De Vivo's research is to bolster understanding cancer etiology, specifically understanding the relationship between genetic variation and disease risk for future prevention. Dr. De Vivo has analyzed samples from the participants of the Nurses Health Study, the Health Professional Follow-up Study (HPFS), Women's Health Study (WHS), and the National Institutes of Health PLCO cohort. Additionally, she has evaluated participants from established case-control studies to determine genetic susceptibility to multiple primary cancers, breast cancer, ovarian cancer, infertility, bladder cancer and endometrial cancer.

 

 
Elizabeth Karlson, M.D.

Associate Professor of Medicine, HMS
Medicine, Brigham and Women's Hospital
(617) 732-5325
Dr. Elizabeth Wood Karlson is a population scientist focusing on the epidemiology and outcomes of rheumatic disease. Her research is focused on epidemiology and outcomes of rheumatic diseases, in particular Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). The group has developed innovative epidemiologic tools for testing hypotheses in populations, investigated the epidemiology of rheumatic diseases in large cohorts of female health professionals, studied predictors of outcome in RA and SLE and established a large SLE Registry. Dr. Karlson is a co-investigator with the Partners Biorepository for Medical Discovery.

 

 
Birgit Funke, Ph.D., FACMG

Assistant Professor of Pathology, MGH/HMS
Director of Clinical Research and Development

Laboratory for Molecular Medicine, PCPGM

(617) 768-8467

bfunke@partners.org

Birgit Funke, Ph.D., FACMG is the Director of Clinical Research and Development, Associate Laboratory Director of the Laboratory for Molecular Medicine (LMM) at PCPGM and is an Assistant Professor of Pathology at MGH/Harvard Medical School. She currently oversees genetic testing and test development in the various areas of disease at the LMM. She has authored and co-authored many publications focusing on a wide array of topics, most recently incentive learning and memory in mice. Currently, Dr. Funke focuses on genetic testing with emphasis on genetically heterogeneous cardiovascular diseases, with the goal of defining the genetic basis for these disorders and developing comprehensive tests using new emerging molecular technologies. In addition, she is interested in developing genetic tests for common, complex disorders, working to understand the genetic variants that have been linked with psychotic and affective disorders.

 

 
Robert Green, M.D., M.P.H.

Associate Professor of Medicine

Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School
Associate Director for Research, Partners HealthCare Center for Personalized Genetic Medicine
(617) 264-5834
rcgreen@genetics.med.harvard.edu

 

Robert C. Green, MD, MPH is Associate Professor of Medicine in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School and Associate Director for Research at the Partners HealthCare Center for Personalized Genetic Medicine. His research interests have evolved from a focus on clinical trials and genetic epidemiology to a focus on translational genomics and health outcomes. He has been continuously funded by NIH for 21 years and has published over 300 articles. Key contributions have included the development of risk estimates based on family history and genetic markers, leadership and analysis of large multi-center treatment and prevention trials, including trials enriched through family history, and design, leadership and future planning of the first large-scale randomized clinical trials in translational genetics. He serves on a number of advisory, editorial and grant review boards and is a regular member of the National Human Genome Research Institute (NHGRI) study section on Ethical, Legal and Social Issues (ELSI) and Human Genetics. He has been invited to participate in National Institutes of Health (NIH) planning workshops on the future of genomic medicine, and has been a featured or plenary speaker on translational genomics and personalized medicine at meetings of the World Science Festival, the National Coalition for Health Professional Education in Genetics, the American Academy of Neurology, the Consumer Genetics Conference, the World Congress of Psychiatric Genetics, the American Society of Human Genetics, the National Press Club and the Bio IT World Conference. He is a Board Member of the Council for Responsible Genetics and was a plenary speaker on the topic of “Translational Genomics” at the Presidential Symposium of the 2011 American College of Medical Genetics and Genomics.

 

Dr. Green graduated from Amherst College and the University of Virginia School of Medicine before fulfilling a residency in neurology at Harvard Medical School's Longwood Neurology Program. Following this, he completed research fellowships at the Beth Israel Hospital and Children's Hospital in Boston, winning both the William B. Lennox Research Fellowship and the Wilder Penfield Research Fellowship. Dr. Green obtained additional training in Epidemiology, receiving a Masters in Public Health from the Rollins School of Public Health at Emory University. In 1999, Dr. Green joined the faculty of Boston University where he was Professor of Neurology, Genetics and Epidemiology in the Schools of Medicine and Public Health. He was recruited to BWH and HMS after completing a fellowship in genetics at Harvard Medical School and becoming board-certified in medical genetics in 2011.

 

 
Kent Lewandrowski, M.D.

Professor of Pathology, HMS
Pathology
Massachusetts General Hospital
(617) 726-2275

Kent Lewandrowski, M.D. is the Associate Chief for Laboratory and Molecular Medicine at the Massachusetts General Hospital. He is a Professor of Pathology at Harvard Medical School with research interests in pancreatic pathology and the evaluation of point-of-care technologies. Dr. Lewandrowski was trained in anatomic and clinical pathology at the Massachusetts General Hospital and has been on the staff of the department of Pathology since 1991. He is also editor in chief of the medical journal "Point of Care: The Journal of Near Patient Testing Technology".

 

 
Joan M. Stoler, M.D.

Associate Professor of Pediatrics, HMS
Pediatrics
Children’s Hospital Boston
(617) 355-8315
 

Joan M. Stoler, M.D., has been the Program Director of the Harvard Medical School Genetics Training Program since 2012. She currently serves as Interim Associate Chief of the Division of Genetics in the Division of Genetics at Children’s Hospital Boston. In this capacity, she oversees all clinical operations of the Division, including the clinical programs in Genetics and Metabolism at the Longwood campus as well as the Children's Hospital satellites. The programs she oversees provide residency training for medical genetics, as well as postgraduate training in the laboratory specialties of clinical cytogenetics, molecular genetics, and biochemical genetics.

 

 
Jordan Smoller, M.D., Sc.D.

Professor of Psychiatry, HMS
Psychiatry
Massachusetts General Hospital
617-724-0835

Dr. Jordan Smoller is Associate Vice Chair of the MGH Department of Psychiatry and Director of Psychiatric Genetics. He is Professor of Psychiatry at Harvard Medical School and Associate Professor in the Department of Epidemiology at the Harvard School of Public Health in Boston. He is Director of the Psychiatric and Neurodevelopmental Genetics Unit in the MGH Center for Human Genetics Research. Dr. Smoller also serves as co-director of the Genetics and Genomics Unit of the MGH Clinical Research Program. At Harvard Medical School, he is Director of the Translational Genetics and Bioinformatics Program of the Harvard Catalyst. He is also Science Director of the Science of Health and Development Initiative at the Center on the Developing Child at Harvard University. Dr. Smoller is an Associate Member of the Broad Institute and a Senior Scientist at the Broad’s Stanley Center for Psychiatric Research. The focus of Dr. Smoller’s research interests has been the identification of genetic determinants of childhood and adult psychiatric disorders. Dr. Smoller and colleagues have also been studying pharmacogenetic predictors of treatment response and the ways in which advances in genetics may impact clinical practice in psychiatry. He is an author of more than 150 scientific articles, book chapters and reviews; the recipient of numerous research awards; and a principal investigator on NIH-funded studies of the genetics of anxiety and the genetics of bipolar disorder, major depression and schizophrenia.

 

 
Susan Slaugenhaupt, Ph.D.

Professor of Neurology, HMS
Neurology, Massachusetts General Hospital

Sue Slaugenhaupt received her Ph.D. in Human Genetics from the University of Pittsburgh in Pittsburgh, PA, USA. She is a Professor of Neurology in the Center for Human Genetic Research at Massachusetts General Hospital and Harvard Medical School. Her research interests include the discovery and characterization of human disease genes and the role of mRNA splicing in human disease. Dr. Slaugenhaupt's current work focuses on two neurological disorders, familial dysautonomia (FD) and mucolipidosis type IV (MLIV), as well as the common cardiac disorder mitral valve prolapse (MVP). Discoveries in Sue's laboratory have led to the successful implementation of critical population screening for FD and MLIV, in addition to a clinical trial of the first therapeutic for FD that directly targets the molecular defect. Sue and her team have further developed a potential treatment for a genetic disease that directly targets the mRNA splicing mechanism. Given the frequency of splicing mutations, a genome-wide assessment of known mutations will ultimately allow for the development of a panel of drugs that can shift the ratio of mRNA isoforms as a means of treating human genetic disease.

 

 
Raju Kucherlapati, Ph.D.

Paul C. Cabot Professor of Genetics, HMS
Genetics
HMS New Research Building
(617) 732-6378
rkucherlapati@partners.org

Raju Kucherlapati, Ph.D. has contributed to several areas of research, including homologous recombination, human gene mapping, generation of physical maps of the human genome with emphasis on human chromosome 12, development of techniques to modify genes in mammalian cells and in cloning many human disease genes. He serves as Faculty advisor to PCPGM and leads the Center’s annual Personalized Medicine Conference and its annual William K. Bowes, Jr. Award in Medical Genetics. In 2001, Dr. Kucherlapati became the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG), stepping down in 2008. He is a fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Kucherlapati was a founder of Cell Genesys, Abgenix and Millennium Pharmaceuticals. He currently serves on the boards of privately held AVEO Pharmaceuticals and Enlight Biosciences.

 

 
Matthew Lebo, Ph.D.

Instructor of Pathology, HMS
Director of Bioinformatics, PCPGM

Assistant Laboratory Director, Laboratory for Molecular Medicine, PCPGM
(617) 768-8292
 

 

 

 
Sami S. Amr, Ph.D.

Instructor of Pathology, HMS
Director, PCPGM Research Cores

Assistant Laboratory Director, Laboratory for Molecular Medicine, PCPGM
(617) 768-8377
 

 

 
Cynthia Morton, Ph.D.

W.L. Richardson Professor of Ob/Gyn, HMS
Professor of Pathology, HMS
Uterine Fibroids, Hereditary Deafness
HMS New Research Building, 160D
(617) 525-4535
cmorton@partners.org

Cynthia Morton, Ph.D. is the William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology and Professor of Pathology at Harvard Medical School. She is an Associate Director of Education for the PCPGM and is the Principal Investigator for the HMS Training Grant that supports the HMS Genetics Training Program that is administered by PCPGM. Her research interests are in molecular cytogenetics, hereditary deafness, genetics of uterine leiomyomata, hereditary hearing loss, and cytogenetic approaches to gene discovery for developmental disorders. Her full-time academic laboratory contributed to the development of diagnostic testing for chromosome studies that cross the lifespan, which include preimplantation and prenatal diagnostics, perinatal and childhood studies in the evaluation of congenital and developmental disorders, infertility and pregnancy loss studies, and cytogenetics of leukemias, lymphomas and solid tumors. Her laboratory has been a major site for training laboratory geneticists in clinical cytogenetics.

 

 
Soumya Raychaudhuri, M.D., Ph.D.

Instructor in Medicine, HMS
Divisions of Genetics & Rheumatology
HMS New Research Building
(617) 525-4484
sraychaudhuri@partners.org

Soumya Raychaudhuri, M.D., Ph.D. has recently been recruited as one of our Center's new faculty members. Soumya will be an Assistant Professor in the Division of Genetics and the Division of Rheumatology, Immunology and Allergy, both within the Department of Medicine at BWH. His Ph.D. is in Biomedical Informatics and he recently completed his postdoctral training in statistical genetics under Mark Daly at the Broad Institute. He is interested in using human genetics to understand key pathogenic pathways that cause human disease, with a particular focus on rheumatoid arthritis and other autoimmune diseases. He works closely with Robert Plenge and other investigators at the Broad Institute to help identify risk variants for Rheumatoid Arthritis. He also uses methods in bioinformatics, systems biology and statistical genetics to help elucidate critical pathways that predispose humans to autoimmune disease. He has contributed to many publications and lectures at International genetics forum. He is the recipient of a K08 award from the NIH and was recognized as an American College of Rheumatology Distinguished Fellow in 2009.

To learn more about his lab, you can go to the link below.
http://immunogenomics.hms.harvard.edu/index.html

 

 
Heidi L. Rehm, Ph.D., FACMG

Associate Professor of Pathology, BWH/HMS
Chief Laboratory Director, Laboratory for Molecular Medicine

Director, ABMG Clinical Molecular Genetics Training Program
Hearing Loss, Usher syndrome
Laboratory for Molecular Medicine, PCPGM
(617) 768-8576 - (Carly Mailly - Assistant)
hlrehm@partners.org

Heidi Rehm, Ph.D. was recruited in 2001 to build the Laboratory for Molecular Medicine at PCPGM and serves as its Chief Laboratory Director. She is a board-certified clinical molecular geneticist and Associate Professor of Pathology at  Harvard Medical School with appointments at BWH, MGH and Children’s Hospital Boston. Her undergraduate degree is from Middlebury College, her graduate degree in Genetics is from Harvard University and her postdoctoral and fellowship training was at HMS. Heidi has served as the Director of the ABMG Clinical Molecular Genetics Training Program at HMS since 2006. In addition to running the LMM and the molecular training program, she also conducts research in hearing loss, Usher syndrome, cardiomyopathy and the use of IT in enabling personalized medicine.

 

 

 
Patrick Sluss, Ph.D.

Associate Professor of Pathology, HMS
Massachusetts General Hospital
(617) 726-4352
sluss.patrick@mgh.harvard.edu

Patrick Sluss, Ph.D., is Associate Professor of Pathology at Harvard Medical School and Co-Director of the Partners Biorepository for Medical Discovery (PBMD) at Massachusetts General Hospital where he is the Director of Special Chemistry in the Clinical Pathology Core Laboratories and co-Director of the Clinical Laboratory Research Core facility. His research activities were focused on ovarian physiology. After completion of an NIH Fellowship in Biochemistry at Albany Medical College, Dr Sluss’ NIH funded research involved ovarian biomarker discovery and analytical method development primarily concerning ovarian peptide signaling systems. Since joining the MGH in 1991, Dr Sluss has increasingly focused on biomarker translational research, improving clinical steroid measurement technologies, and management of patient care testing.

 

 
Scott T. Weiss, M.D., M.S.

Professor of Medicine, HMS
Scientific Director, PCPGM
Associate Director of Channing Laboratory, Department of medicine, BWH

New Research Building
77 Avenue Louis Pasteur, Suite 250, Boston, MA 02115
(617) 525-2278 Channing
(617) 525-5136 NRB
scott.weiss@channing.harvard.edu

Dr. Weiss is the Scientific Director of the Partners HealthCare Center for Personalized Genetic Medicine (PCPGM). In this capacity he leads over 100 faculty and staff in PCPGM’s CLIA-certified Laboratory for Molecular Medicine; its research core laboratories; the Partners biobanking initiative known as the Partners Biorepository for Medical Discovery (PBMD); and educational programs for healthcare providers, investigators, and the public. Dr. Weiss is also Associate Director of Channing Laboratory in the Department of Medicine of Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. In this capacity, he leads a 29 investigator and 110 person research group examining the environmental and genetic origins of asthma and COPD.

Dr. Weiss’ initial work concerned the role of airways responsiveness and environmental tobacco smoke exposure in asthma and COPD, the effect of allergen exposure and airways responsiveness on markers of inflammation and the combined effect of these factors on the development of COPD. His recent work has focused on the genetics of asthma and on novel environmental exposures such as vitamin D and its role in asthma development. His laboratory is the only laboratory in the world that has an active NIH research program in the areas of asthma genetics, asthma pharmacogenetics, and COPD genetics. He is the principal investigator or co-investigator on six separate NHLBI-funded grants, including a MERIT award, in the area of the genetics of asthma and asthma pharmacogenetics. These grants involve several large asthma populations and three consortia projects involving investigators across the US.

He is the Principal Investigator of a long standing T-32 Training grant (HL-07427) and a K-12 training grant in genetics and genomics. Dr. Weiss has had 33 trainees in the last 15 years, 31 of these trainees are still in academic medicine. He has served in an advisory capacity for NHLBI for the past 25 years. Dr. Weiss is the author of over 500 scientific publications and four books.